About the Combat Melanoma Session
Melanoma is an aggressive form of skin cancer. It is characterized by the abnormal growth of pigment-producing cells (melanocytes) in the skin. Melanoma is the most severe type of skin cancer and is very difficult to treat. It is important to be aware of any changes in size, shape, or color of existing moles or the development of a new mole. Early detection is the key to successful treatment of melanoma and prevention of its progression into advanced stages. Sunlight is the main source of ultraviolet radiation which is known to trigger and worsen this condition. Therefore, it is important to use protective clothing and sunscreens that are designed to block ultraviolet (UV) radiation. Other preventive strategies include avoidance of tanning beds and other forms of artificial UV radiation, and regular examinations by a dermatologist to detect any early signs of skin cancer. The treatment of melanoma varies depending on the stage and severity of the condition. Most cases of melanomas are treated with surgical excision to remove affected areas of skin. This may involve a wide excision of normal tissue around the malignant area to help prevent recurrence in the future. Adjuvant treatments may also be used in some cases to reduce the risk of tumor spread. Radiation therapy, chemotherapy, and immunotherapy are the main options for treating advanced stages of melanoma. No matter what stage, treating melanoma is challenging. The goal of treatment is to stop the growth and spread of cancer while minimizing side effects. By closely monitoring the mole or lesion, paying attention to any changes, and working with an experienced dermatologist, the risk of progression can be minimized.
Featured Speakers — Combat Melanoma 2027
Speaker lineup for this track will be announced soon.
Browse all speakers →Recent Research Presented at Combat Melanoma Sessions
Selected abstracts from this track will be published here.
Related Scientific Sessions at IDC 2027
Why Attend the Combat Melanoma Conference 2027
Earn CPD Credit
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Present Your Research
Oral and poster slots for original Combat Melanoma work, reviewed by the scientific committee.
Network Globally
Meet researchers, clinicians, and industry leaders from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Combat Melanoma research and practice.
Hybrid Flexibility
Attend in person in Rome or join virtually — same programme, same certificate.
Join IDC 2027 for the Combat Melanoma track
Oral and poster slots for your work — in person in Rome or online. Not presenting? Attend as a delegate to learn from the field.
Combat Melanoma Conference 2027 — FAQs
What is the Combat Melanoma track at IDC 2027?
The Combat Melanoma track is a dedicated stream within IDC 2027 covering the latest research, clinical innovation, and best practice in Combat Melanoma. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Combat Melanoma sessions?
Researchers, clinicians, educators, doctoral students, and industry leaders with an interest in Combat Melanoma are all welcome — whether presenting or attending.
Can I present my research in the Combat Melanoma track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Combat Melanoma sessions?
Yes. IDC 2027 is a hybrid conference — attend the Combat Melanoma track in person in Rome or join live online, with on-demand access afterward.
Join the IDC 2027 delegation
Rome · June 21–23, 2027 · Hybrid · in-person & virtual
Attend without presenting.